Individualized ocular characteristics should be considered before starting GLP-1 RA therapies for weight loss and diabetes ...

A study in weight loss drugs where one third of participants were given a placebo turned out to have some impressive results.

Novo Nordisk's early lead in weight-loss drugs fades as Eli Lilly surges ahead with more effective therapies and faster ...

Among patients who experienced an early cardiovascular event, those treated with semaglutide had approximately 40% fewer ...

An international study reveals that the drug can reverse liver damage in patients. An international study led by researchers ...

GLP-1 drugs like Ozempic show widespread promise beyond weight loss/diabetes, but cost and supply limit broader adoption.

Researchers find tirzepatide more effective than semaglutide for weight loss in a 72-week trial, with significant reductions ...

Some consumers take tiny doses of Ozempic and other GLP-1 drugs or stretch out doses to cut costs and side effects.

Locally produced versions of drugs like Semaglutide are helpful for patients with obesity and diabetes, but unprescribed use raises concerns ...

The Food and Drug Administration is cracking down on copycat versions of Ozempic — the brand name of semaglutide — and ...

Novo has a strong balance sheet and ended 2024 with about DKK 26 billion in cash and marketable securities and DKK 103 billion of debt (following the acquisition of Catalent manufacturing sites in ...